title: High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc.
authors.affiliation: Department of Neuropathology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany.
authors.forename: Lidia
authors.initials: L
authors.lastname: Stork
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Brück
authors.forename: Amit
authors.initials: A
authors.lastname: Bar-Or
authors.forename: Imke
authors.initials: I
authors.lastname: Metz
mesh_terms: D001402:B-Lymphocytes / Q000378:metabolism; D065100:CCR5 Receptor Antagonists / Q000627:therapeutic use*; D015496:CD4-Positive T-Lymphocytes; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism; D003510:Cyclohexanes; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D007968:Leukoencephalopathy, Progressive Multifocal / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D000077592:Maraviroc; D009103:Multiple Sclerosis / Q000188:drug therapy; D000069442:Natalizumab / Q000627:therapeutic use; D019713:Receptors, CCR5 / Q000096:biosynthesis*; D014230:Triazoles
chemical_list: D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D000069442:Natalizumab; D019713:Receptors, CCR5; D014230:Triazoles; D000077592:Maraviroc